Evaluation of MMR Concordance Based on Either International Scale (IS) or National Comprehensive Cancer Network (NCCN) Criteria Using Reconstructed “Virtual” CML Patient Profiles From the REVEAL BCR-ABL Methods Comparison Study,
Poluru L. Reddy(University of Chicago Medical Center), Meir Wetzler, Feng Yang(Fudan University), Andrew P. Stein(University of Wisconsin–Madison), Mike M. Moradian(Kaiser Permanente), Andre Mignault(Novartis (United States)), Paul Choppa(American Association of Critical-Care Nurses), Shasha Wang(Chinese PLA General Hospital), Nicholas T. Potter(Molecular Pathology Laboratory Network (United States)), Michael Quigley(Scripps Health), Brian P. Mullaney(Cornell University), Diego Ossa(Novartis (Switzerland)), Christopher D. Watt(University of Pennsylvania), Brian Manning(Novartis (United States)), Holger Höfling(Novartis (Switzerland))
Cited by 0
Related Papers
<i>IDH1</i> and <i>IDH2</i> Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study
|Journal of Clinical Oncology|2010|764
Efficacy and Safety of Ixabepilone (BMS-247550) in a Phase II Study of Patients With Advanced Breast Cancer Resistant to an Anthracycline, a Taxane, and Capecitabine
|Journal of Clinical Oncology|2007|392
BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive Leukemia
|Cancer Cell|2014|366